Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss.

× No keyword cloud information.

8 in total

1. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Authors: C Brüggemann; M C Kirchberger; S M Goldinger; B Weide; A Konrad; M Erdmann; D Schadendorf; R S Croner; L Krähenbühl; K C Kähler; C Hafner; W Leisgang; F Kiesewetter; R Dummer; G Schuler; M Stürzl; L Heinzerling
Journal: J Cancer Res Clin Oncol Date: 2017-06-14 Impact factor: 4.553

Review 2. Checkpoint Inhibitors.

Authors: Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal: Dtsch Arztebl Int Date: 2019-02-22 Impact factor: 5.594

Review 3. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.

Authors: Hiroki Nagai; Manabu Muto
Journal: Int J Clin Oncol Date: 2018-03-07 Impact factor: 3.402

4. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544

5. Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

Authors: Niels J Brouwer; John B A G Haanen; Martine J Jager
Journal: Ocul Oncol Pathol Date: 2017-02-02

Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss.

1. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Review 2. Checkpoint Inhibitors.

Review 3. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.

4. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

5. Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

Review 6. Ocular Toxicity of Targeted Anticancer Agents.

7. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

8. Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma.